Soluble Receptor for Advanced Glycation Endproducts Is Decreased in Patients with Juvenile Idiopathic Arthritis (ERA Category) and Inversely Correlates with Disease Activity and S100A12 Levels

REFERENCES

1. 1.↵
   1. Schmidt AM,
   2. Yan SD,
   3. Yan SF,
   4. Stern DM

   . The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949–55.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Schmidt AM,
   2. Yan SD,
   3. Yan SF,
   4. Stern DM

   . The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000;1498:99–111.

   OpenUrlPubMed
3. 3.↵
   1. Sparvero LJ,
   2. Asafu-Adjei D,
   3. Kang R,
   4. Tang D,
   5. Amin N,
   6. Im J,
   7. et al.

   RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009;7:17–38.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Li Lin,
   2. Park S,
   3. Lakatta EG

   . RAGE signaling in inflammation and arterial aging. Front Biosci 2009;14:1403–13.

   OpenUrlPubMed
5. 5.↵
   1. Chavakis T,
   2. Bierhaus A,
   3. Al-Fakhri N,
   4. Schneider D,
   5. Witte S,
   6. Linn T,
   7. et al.

   The pattern recognition receptor (RAGE) is a counter receptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003;198:1507–15.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Pullerits R,
   2. Brisslert M,
   3. Jonsson IM,
   4. Tarkowski A

   . Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta 2 integrin Mac-1. Arthritis Rheum 2006;54:3898–907.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Donato R

   . Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999;1450:191–231.

   OpenUrlPubMed
8. 8.↵
   1. Wittkowski H,
   2. Frosch M,
   3. Wulffraat N,
   4. Goldbach-Mansky R,
   5. Kallinich T,
   6. Kuemmerle-Deschner J,
   7. et al.

   S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 2008;58:3924–31.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Foell D,
   2. Wittkowski H,
   3. Roth J

   . Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007;3:382–90.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Hofmann MA,
    2. Drury S,
    3. Fu C,
    4. Qu W,
    5. Taguchi A,
    6. Lu Y,
    7. et al.

    RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889–901.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Pullerits R,
    2. Bokarewa M,
    3. Dahlberg L,
    4. Tarkowski A

    . Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005;7:R817–24.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Chayanupatkul M,
    2. Honsawek S

    . Soluble receptor for advanced glycation end products (sRAGE) in plasma and synovial fluid is inversely associated with disease severity of knee osteoarthritis. Clin Biochem 2010;43:1133–7.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Stewart C,
    2. Cha S,
    3. Caudle RM,
    4. Berg K,
    5. Katz J

    . Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjögren’s syndrome. Rheumatol Int 2008;28:771–6.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Wittkowski H,
    2. Hirono K,
    3. Ichida F,
    4. Vogl T,
    5. Ye F,
    6. Yanlin X,
    7. et al.

    Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum 2007;56:4174–81.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Chen YS,
    2. Yan W,
    3. Geczy GL,
    4. Brown MA,
    5. Thomas R

    . Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther 2009;11:R39–50.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Petty RE,
    2. Southwood TR,
    3. Manners P,
    4. Baum J,
    5. Glass DN,
    6. Goldenberg J,
    7. et al.

    International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390–2.

    OpenUrlFREE Full Text
17. 17.↵
    1. Foell D,
    2. Wittkowski H,
    3. Hammerschmidt I,
    4. Wulffraat N,
    5. Schmeling H,
    6. Frosch M,
    7. et al.

    Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 2004;50:1286–95.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Baillet A,
    2. Trocmé C,
    3. Berthier S,
    4. Arlotto M,
    5. Grange L,
    6. Chenau J,
    7. et al.

    Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology 2010;49:671–82.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Sunahori K,
    2. Yamamura M,
    3. Yamana J,
    4. Takasugi K,
    5. Kawashima M,
    6. Makino H

    . Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2006;54:97–104.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Hou FF,
    2. Jiang JP,
    3. Guo JQ,
    4. Wang GB,
    5. Zhang X,
    6. Stern DM,
    7. et al.

    Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J Am Soc Nephrol 2002;13:1296–306.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Tolboom TC,
    2. Pieterman E,
    3. van der Laan WH,
    4. Toes RE,
    5. Huidekoper AL,
    6. Nelissen RG,
    7. et al.

    Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis 2002;61:975–80.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Pullerits R,
    2. Bokarewa M,
    3. Dahlberg L,
    4. Tarkowski A

    . Synovial fluid expression of autoantibodies specific for RAGE relates to less erosive course of rheumatoid arthritis. Rheumatology 2007;46:1367–71.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Ferrante E,
    2. Vazzana N,
    3. Santilli F,
    4. Di Cicco M,
    5. Lauriti C,
    6. Di Battista L,
    7. et al.

    Determinants of thromboxane biosynthesis in rheumatoid arthritis: Role of RAGE and oxidant stress. Free Radic Biol Med 2010;49:857–64.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Ellis JA,
    2. Munro JE,
    3. Ponsonby AE

    . Possible environmental determinants of juvenile idiopathic arthritis. Rheumatology 2010;49:411–25.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Wang Y,
    2. Wang H,
    3. Piper MG,
    4. McMaken S,
    5. Mo X,
    6. Opalek J,
    7. et al.

    sRAGE induces human monocyte survival and differentiation. J Immunol 2010;185:1822–35.

    OpenUrlAbstract/FREE Full Text